Searchable abstracts of presentations at key conferences in endocrinology

ea0081p29 | Adrenal and Cardiovascular Endocrinology | ECE2022

The changing face of drug-induced adrenal insufficiency in the food and drug administration adverse event reporting system

Raschi Emanuel , Fusaroli Michele , Massari Francesco , Mollica Veronica , Repaci Andrea , Ardizzoni Andrea , Poluzzi Elisabetta , Pagotto Uberto , Di Dalmazi Guido

Importance: Adrenal insufficiency is a life-threatening condition complicating heterogenous disorders across various disciplines, with challenging diagnosis and a notable drug-induced component.Objective: To describe the spectrum and main features of drug-induced adrenal insufficiency through adverse drug event reports received by the Food and Drug Administration (FDA).Design: We conducted a retrospective disproportionality analysi...

ea0063p1040 | Interdisciplinary Endocrinology 2 | ECE2019

Diabetes and Nivolumab: 2 clinical cases compared

Preiato Valentina Lo , Salvagni Stefania , Ribichini Danilo , Ardizzoni Andrea , Pagotto Uberto , Pelusi Carla

Monoclonal antibodies against the Programmed cell death-1 protein (PD-1) are a new treatment for advanced cancer. Endocrine and metabolic diseases are known to be frequently associated with this class of drugs. We describe two cases of Nivolumab-induced diabetes mellitus.Case 1: A 73-year-old man with a mutated BRAF-V600K advanced stage melanoma was treated with Nivolumab (240 mg IV every 2 weeks). He had normal-weight (BMI: 21.6 Kg/mq), and no previous ...

ea0070aep999 | Thyroid | ECE2020

Pembrolizumab inducing thyroid diseases: Are there differences between patients treated for lung carcinomas and those for lymphomas?

Lo Preiato Valentina , Buganè Anna , Casadei Beatrice , Salvagni Stefania , Argnani Lisa , Ardizzoni Andrea , Luigi Zinzani Pier , Pagotto Uberto

Background: In the last years, Pembrolizumab has been used to treat solid and lymphatic neoplasms, showing improved patients’ survival. Due to its mechanism of action, Pembrolizumab may be responsible of several immune-related adverse events (irAEs). The most frequent endocrine-irAEs reported are thyroid diseases.Aims: The aim of this study was to evaluate differences in thyroid disease incidence and presentation between patients treated for lung c...

ea0056p645 | Endocrine Disruptors | ECE2018

Endocrine related adverse events associated with immune checkpoint blockade therapy: a retrospective analysis

Preiato Valentina Lo , Salvagni Stefania , Gianni Caterina , Ribichini Danilo , Bianchi Nicola , Pagotto Uberto , Ardizzoni Andrea , Pelusi Carla

Background: Immune checkpoint inhibitors (ICI) have become a clinically validated treatment for numerous types of tumor including melanoma, lung, and kidney carcinoma. These treatments can cause immune-related adverse events affecting several organs including the endocrine system.Aims: The aim of this study was to characterize the type and the onset of the ICI associated-endocrinopathies.Materials and methods: This retrospective co...